The blood-brain barrier: Bottleneck in brain drug development

By W. Pardridge. NeuroRx, 2005

2,128 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/d2bb1ef7f1e3c5ab452b107accdef1cf32218858

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Amanda F. Levy
2. Mao Ye
3. Peter C. Searson
4. Jeffrey D. Rothstein
5. R. Gabathuler
6. D. Bergles
7. Andrew D. Wong

In Neurology

1. Behnam Noorani
2. Amanda F. Levy
3. Mao Ye
4. Peter C. Searson
5. Jeffrey D. Rothstein
6. L. Cucullo
7. Hossam Kadry
8. R. Gabathuler

In Oncology

1. Behnam Noorani
2. Elif S. Seven
3. Zhili Peng
4. Amanda F. Levy
5. Mao Ye
6. Peter C. Searson
7. R. Leblanc
8. Jeffrey D. Rothstein

Citations in the corpus

• Crossing the blood‐brain barrier with nanoparticles (2018, background): “Small lipophilic molecules (< 400 Da) diffuses passively through endothelial cells [65].”
• The blood-brain barrier: an engineering perspective (2013, positive): “The barrier function of the BBB is critical for regulating transport to the brain, but also represents a significant roadblock in delivering drugs to the brain (Pardridge, 2003, 2005, 2006, 2008, 2010; Hawkins and Davis, 2005; Ohtsuki and Terasaki, 2007).”
• Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. (2010, methodology): “○ Using the antibody approach against TR, the receptor specific mAb binds to the receptor on the endothelial cells, and allows the associated therapeutic agent to cross the BBB via receptor-mediated transcytosis (Pardridge, 2003; Zhang and Pardridge, 2005).”
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations. (2010, background): “Despite the immense network of the cerebral vasculature, systemic delivery of therapeutics to the central nervous system (CNS) is not effective for greater than 98% of small molecules and for nearly 100% of large molecules.(1) The lack of”
• Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio (2015, background): “Currently, the main approach to deliver drugs across the BBB is to utilize endogenous transport mechanisms (27).”
• Mechanism of intranasal drug delivery directly to the brain (2018, background): “Together, these mechanisms restrict access to the CNS via the BBB for 98% of small molecules and nearly 100% of large molecules [7].”
• A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity (2020, background): “These integrated barrier systems, while protecting the brain from potentially harmful compounds, are also the major obstacle for delivering drugs into the CNS [23].”